ERBB2 and breast cancer: Our mathematical model-based study points out that the combination therapy using trastuzumab (anti-HER2, mAb) and BMS-202 (anti-PD-1/PD-L1, SmI) results in a significant growth inhibition of HER2+ BC cell lines compared with monotherapies even in an immune cell deprived environment.